North American Prodromal Synucleinopathy Consortium

REM sleep behavior disorder (RBD) is a rare disorder where people act out their dreams.
People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy
bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy
type. The North American Prodromal Synucleinopathy (NAPS) Consortium was formed with the
purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a
neuroprotective treatment against synucleinopathies. The NAPS Consortium will collect
standardized clinical assessments, biofluids, and other data in order to develop biomarkers
for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready
registry of participants. Participants procedures will include a ~2-hour clinical assessment
(medical history and physical exam), questionnaires, blood draw, and (at select sites)
optional lumbar puncture.

Inclusion Criteria:

- Idiopathic REM sleep behavior disorder

Exclusion Criteria:

- REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia,
Parkinson's Disease, etc)

- Other neurological disorder